Skip to main content
Journal cover image

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.

Publication ,  Journal Article
Abonour, R; Wagner, L; Durie, BGM; Jagannath, S; Narang, M; Terebelo, HR; Gasparetto, CJ; Toomey, K; Hardin, JW; Kitali, A; Gibson, CJ ...
Published in: Ann Hematol
December 2018

Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Presented here is an analysis of HRQoL in a Connect MM registry cohort of patients who received ASCT ± maintenance therapy. The Connect MM Registry is one of the earliest and largest, active, observational, prospective US registry of patients with symptomatic newly diagnosed MM. Patients completed the Functional Assessment of Cancer Therapy-MM (FACT-MM) version 4, EuroQol-5D (EQ-5D) questionnaire, and Brief Pain Inventory (BPI) at study entry and quarterly thereafter until death or study discontinuation. Patients in three groups were analyzed: any maintenance therapy (n = 244), lenalidomide-only maintenance therapy (n = 169), and no maintenance therapy (n = 137); any maintenance and lenalidomide-only maintenance groups were not mutually exclusive. There were no significant differences in change from pre-ASCT baseline between any maintenance (P = 0.60) and lenalidomide-only maintenance (P = 0.72) versus no maintenance for the FACT-MM total score. There were also no significant differences in change from pre-ASCT baseline between any maintenance and lenalidomide-only maintenance versus no maintenance for EQ-5D overall index, BPI, FACT-MM Trial Outcomes Index, and myeloma subscale scores. In all three groups, FACT-MM, EQ-5D Index, and BPI scores improved after ASCT; FACT-MM and BPI scores deteriorated at disease progression. These data suggest that post-ASCT any maintenance or lenalidomide-only maintenance does not negatively impact patients' HRQoL. Additional research is needed to verify these findings.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Hematol

DOI

EISSN

1432-0584

Publication Date

December 2018

Volume

97

Issue

12

Start / End Page

2425 / 2436

Location

Germany

Related Subject Headings

  • United States
  • Thalidomide
  • Registries
  • Quality of Life
  • Prospective Studies
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Maintenance Chemotherapy
  • Lenalidomide
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Abonour, R., Wagner, L., Durie, B. G. M., Jagannath, S., Narang, M., Terebelo, H. R., … Rifkin, R. M. (2018). Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. Ann Hematol, 97(12), 2425–2436. https://doi.org/10.1007/s00277-018-3446-y
Abonour, Rafat, Lynne Wagner, Brian G. M. Durie, Sundar Jagannath, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, et al. “Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.Ann Hematol 97, no. 12 (December 2018): 2425–36. https://doi.org/10.1007/s00277-018-3446-y.
Abonour R, Wagner L, Durie BGM, Jagannath S, Narang M, Terebelo HR, et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. Ann Hematol. 2018 Dec;97(12):2425–36.
Abonour, Rafat, et al. “Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.Ann Hematol, vol. 97, no. 12, Dec. 2018, pp. 2425–36. Pubmed, doi:10.1007/s00277-018-3446-y.
Abonour R, Wagner L, Durie BGM, Jagannath S, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Kitali A, Gibson CJ, Srinivasan S, Swern AS, Rifkin RM. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. Ann Hematol. 2018 Dec;97(12):2425–2436.
Journal cover image

Published In

Ann Hematol

DOI

EISSN

1432-0584

Publication Date

December 2018

Volume

97

Issue

12

Start / End Page

2425 / 2436

Location

Germany

Related Subject Headings

  • United States
  • Thalidomide
  • Registries
  • Quality of Life
  • Prospective Studies
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Maintenance Chemotherapy
  • Lenalidomide